Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.

Department of Neurology, Osp. S. Andrea, Via Vittorio Veneto 197, 19100 La Spezia, Italy.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 03/2011; 82(3):306-8. DOI: 10.1136/jnnp.2009.188912
Source: PubMed

ABSTRACT A few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
To analyse the efficacy of rituximab in a large CIDP cohort.
A retrospective, observational and multicentre study on the use of rituximab in CIDP. 13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders.
Nine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1-6) and lasted for a median period of 1 year (range, 1-5).
Rituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occurring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: La polyradiculoneuropathie inflammatoire démyélinisante chronique (PIDC) est une maladie rare, mais la plus fréquente des polyneuropathies dysimmunitaires chroniques. Les enjeux thérapeutiques exigent en premier lieu d’améliorer les critères du diagnostic, qui reste difficile, en particulier dans les formes atypiques. Le second enjeu est d’établir des recommandations pour le traitement de première intention, dans la mesure où les corticoïdes, les immunoglobulines intraveineuses à fortes doses (IgIV) et les échanges plasmatiques (EP) ont démontré leur efficacité dans des essais randomisés controlés. Des publications récentes ont rapporté des résultats originaux dans l’utlisation de différentes voies d’administration des corticoïdes, et également dans l’étude des délais de rechute après un traitement de première intention conduit soit avec les corticoïdes, soit avec les IgIV. Ces résultats pourraient modifier la décision thérapeutique en première intention dans les PIDC en pratique quotidienne. Le troisième enjeu, aujourd’hui le plus complexe, concerne le traitement à long-terme des PIDC, dans la mesure où aucun traitement immunomodulateur n’a démontré son efficacité. Enfin, le dernier enjeu est celui des outils d’évaluation dans les essais randomisés controlés, mais aussi en pratique clinique. L’objectif de cette revue est de faire le point sur les derniers résultats publiés dans le diagnostic, le traitement et l’évaluation des PIDC, et de donner un aperçu de la prise en charge actuelle et future des PIDC.
    Revue Neurologique 10/2014; · 0.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune neuropathies occur when immunologic tolerance to myelin or axonal antigens is lost. Even though the triggering factors and the underling immunopathology have not been fully elucidated in all neuropathy subsets, immunological studies on the patients' nerves, transfer experiments with the patients' serum or intraneural injections, and molecular fingerprinting on circulating autoantibodies or autoreactive T cells, indicate that cellular and humoral factors, either independently or in concert with each other, play a fundamental role in their cause. The review is focused on the main subtypes of autoimmune neuropathies, mainly the Guillain-Barré syndrome(s), the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), the Multifocal Motor Neuropathy (MMN), and the IgM anti-MAG-antibody mediated neuropathy. It addresses the factors associated with breaking tolerance, examines the T cell activation process including co-stimulatory molecules and key cytokines, and discusses the role of antibodies against peripheral nerve glycolipids or glycoproteins. Special attention is given to the newly identified proteins in the nodal, paranodal and juxtaparanodal regions as potential antigenic targets that could best explain conduction failure and rapid recovery. New biological agents against T cells, cytokines, B cells, transmigration and transduction molecules involved in their immunopathologic network, are discussed as future therapeutic options in difficult cases. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 06/2014; 1852(4). · 5.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, in which both cellular and humoral immune responses are involved. The disease is clinically heterogeneous with some patients displaying pure motor form and others also showing a variable degree of sensory dysfunction; disease evolution may also differ from patient to patient, since monophasic, progressive, and relapsing forms are reported. Underlying such clinical variability there is probably a broad spectrum of molecular dysfunctions that are and will be the target of therapeutic strategies. In this review we first explore the biological bases of current treatments and subsequently we focus on the practical management that must also take into account pharmacoeconomic issues.
    Autoimmune diseases. 01/2014; 2014:201657.
    This article is viewable in ResearchGate's enriched format

Full-text (2 Sources)

Available from
May 20, 2014